TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 11114455

Group type: EXPERIMENTAL
Intervention: Television exposure to LSFA skill demonstrations
Number of subjects: 202

Group type: COMPARATOR
Intervention: Control group (no TV exposure)
Number of subjects: 202
Study: 9298135

Group type: EXPERIMENTAL
Intervention: Atopic Dermatitis (AD) group
Number of subjects: 129

Group type: EXPERIMENTAL
Intervention: Allergic Respiratory Disease (ARD) group
Number of subjects: 129

Group type: COMPARATOR
Intervention: Healthy control group
Number of subjects: 129
Study: 8117899

Group type: EXPERIMENTAL
Intervention: Weighted Least Squares (WLS)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Iterative form of WLS
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Independence estimating equations
Number of subjects: 0
Study: 3089467

Group type: EXPERIMENTAL
Intervention: 100 ml iohexol
Number of subjects: 87

Group type: EXPERIMENTAL
Intervention: 50 ml iohexol
Number of subjects: 87

Group type: COMPARATOR
Intervention: Creatinine clearance
Number of subjects: 87

Group type: EXPERIMENTAL
Intervention: Contrast media
Number of subjects: 87

Group type: EXPERIMENTAL
Intervention: Reproducibility of contrast clearance measurement
Number of subjects: 87
Study: 31480979

Group type: EXPERIMENTAL
Intervention: Testosterone administration
Number of subjects: 643

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 643
Study: 29713851

Group type: EXPERIMENTAL
Intervention: Yiqi Fumai lyophilized injection (5.2 g) with 250 ml 5% glucose/sodium injection for 7 days
Number of subjects: 666

Group type: COMPARATOR
Intervention: Standardized western medications (control group) for 7 days
Number of subjects: 666
Study: 26711719

Group type: COMPARATOR
Intervention: M‐Ex‐M (morning and evening metformin doses, with exercise)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: M‐Ex (exercise with evening metformin dose only)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Ex‐M (morning metformin dose only, with exercise)
Number of subjects: 10

Group type: COMPARATOR
Intervention: M‐M (morning and evening metformin doses, without exercise)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Exercise conditions (M‐Ex‐M, M‐Ex, Ex‐M)
Number of subjects: 10
Study: 24447190

Group type: EXPERIMENTAL
Intervention: Disgust condition
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Trait disgust
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: State disgust
Number of subjects: 80

Group type: COMPARATOR
Intervention: Control condition
Number of subjects: 80
Study: 21822142

Group type: EXPERIMENTAL
Intervention: Chest CT interpretation lecture
Number of subjects: 58

Group type: COMPARATOR
Intervention: No lecture (Control)
Number of subjects: 58
Study: 19931965

Group type: EXPERIMENTAL
Intervention: Left nostril for NTI
Number of subjects: 54

Group type: COMPARATOR
Intervention: Right nostril for NTI
Number of subjects: 54
Study: 17963264

Group type: EXPERIMENTAL
Intervention: FOLFOX4 until progression (arm A)
Number of subjects: 37

Group type: EXPERIMENTAL
Intervention: FOLFOX7 for 6 cycles, maintenance without oxaliplatin for 12 cycles, and reintroduction of FOLFOX7 (arm B)
Number of subjects: 37

Group type: COMPARATOR
Intervention: Younger patients (<=75 years)
Number of subjects: 37
Study: 15349656

Group type: EXPERIMENTAL
Intervention: rhEPO 6000IU subcutaneously for 3 times a week and Ferrost sulfatis Et vitamini‐medtech 1 tablet per day for 12 days
Number of subjects: 31

Group type: COMPARATOR
Intervention: Ferrost sulfatis Et vitamini‐medtech (same dose as experimental group)
Number of subjects: 31
Study: 10647546

Group type: EXPERIMENTAL
Intervention: Push frequency at 140% of freely chosen frequency (FCF)
Number of subjects: 8

Group type: COMPARATOR
Intervention: Push frequency at 60% FCF
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Push frequency at freely chosen frequency (FCF)
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Push frequency at 100% FCF
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Push frequency at varying percentages of FCF (60%, 80%, 120%, 140%)
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Push frequency at varying percentages of FCF
Number of subjects: 8
Study: 9028716

Group type: EXPERIMENTAL
Intervention: i.v. 1,25‐dihydroxyvitamin D3
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: oral Etalpha (0.25 microgram)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: i.v. and oral 1,25‐dihydroxyvitamin D3
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: 1,25‐dihydroxyvitamin D3 and insulin
Number of subjects: 12
Study: 8333761

Group type: EXPERIMENTAL
Intervention: Pulse oximetry
Number of subjects: 20
Study: 3591258

Group type: EXPERIMENTAL
Intervention: Heating of inspired humidified gases
Number of subjects: 111

Group type: EXPERIMENTAL
Intervention: Heating mattress
Number of subjects: 111

Group type: EXPERIMENTAL
Intervention: Heat supply (combined measures)
Number of subjects: 111

Group type: COMPARATOR
Intervention: Unwarmed control
Number of subjects: 111
Study: 29958906

Group type: EXPERIMENTAL
Intervention: ADSTEP
Number of subjects: 40
Study: 27735028

Group type: EXPERIMENTAL
Intervention: Low-calorie diet (LC)
Number of subjects: 114

Group type: EXPERIMENTAL
Intervention: Isocaloric diet with 500 mg of metformin twice a day (IM)
Number of subjects: 114

Group type: EXPERIMENTAL
Intervention: Isocaloric diet with 120 mg of orlistat three times a day (IO)
Number of subjects: 114
Study: 25474455

Group type: EXPERIMENTAL
Intervention: Cryosurgery and 5-fluorouracil cream 0.5%
Number of subjects: 60

Group type: COMPARATOR
Intervention: Cryosurgery alone
Number of subjects: 60
Study: 22030098

Group type: EXPERIMENTAL
Intervention: Medium-chain triglycerides (MCT) supplementation prior to exercise
Number of subjects: 11

Group type: COMPARATOR
Intervention: Carbohydrate (CHO) supplementation prior to exercise
Number of subjects: 11
Study: 20512584

Group type: EXPERIMENTAL
Intervention: Maximal strength training (MST) - 4 x 4 repetitions of unilateral dynamic leg press and plantar flexion, 5 days a week for 3 weeks.
Number of subjects: 14

Group type: COMPARATOR
Intervention: Control group (CG) - received 'today's treatment' without additional strength training.
Number of subjects: 14
Study: 18417236

Group type: EXPERIMENTAL
Intervention: Electrocutaneous stimulation over the sural nerve
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Different methods of scoring NFR magnitude
Number of subjects: 0
Study: 15916998

Group type: EXPERIMENTAL
Intervention: Single 20-min walk (one bout)
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Two 10-min walks (accumulated bouts)
Number of subjects: 48

Group type: COMPARATOR
Intervention: No training (control)
Number of subjects: 48
Study: 12660502

Group type: EXPERIMENTAL
Intervention: sirolimus (study group, n=15)
Number of subjects: 33

Group type: COMPARATOR
Intervention: tacrolimus and mycophenolate mofetil (control group, n=18)
Number of subjects: 33
Study: 10729758

Group type: EXPERIMENTAL
Intervention: Ultrasound imaging of Bartholin's cysts
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Follow-up US examination after surgery
Number of subjects: 36
Study: 8861991

Group type: EXPERIMENTAL
Intervention: Implantable insulin pump (IIP)
Number of subjects: 121

Group type: COMPARATOR
Intervention: Multiple daily insulin (MDI)
Number of subjects: 121
Study: 1735400

Group type: EXPERIMENTAL
Intervention: hyperbaric Niphanoid tetracaine (6 or 10 mg)
Number of subjects: 137

Group type: EXPERIMENTAL
Intervention: hyperbaric bupivacaine (6 mg)
Number of subjects: 137

Group type: EXPERIMENTAL
Intervention: hyperbaric Niphanoid tetracaine (6 mg) with adrenaline
Number of subjects: 137

Group type: EXPERIMENTAL
Intervention: hyperbaric bupivacaine (6 mg) with adrenaline
Number of subjects: 137

Group type: EXPERIMENTAL
Intervention: light intravenous supplementation with low doses of fentanyl and/or thiopentone
Number of subjects: 137
Study: 6704006

Group type: EXPERIMENTAL
Intervention: Trabeculectomy
Number of subjects: 71

Group type: COMPARATOR
Intervention: Thermosclerostomy
Number of subjects: 71

Group type: EXPERIMENTAL
Intervention: Both interventions
Number of subjects: 71
Study: 30732192

Group type: EXPERIMENTAL
Intervention: Furazolidone-based quadruple therapy (FZD) for 14 days with esomeprazole, bismuth potassium citrate, and amoxicillin
Number of subjects: 185

Group type: COMPARATOR
Intervention: Clarithromycin-based quadruple therapy (CLA) for 14 days with esomeprazole, bismuth potassium citrate, and amoxicillin
Number of subjects: 185
Study: 29932518

Group type: EXPERIMENTAL
Intervention: Higher protein (HP) infant formula
Number of subjects: 1090
Study: 27422252

Group type: EXPERIMENTAL
Intervention: 50th percentile with incentives (n = 100)
Number of subjects: 286

Group type: EXPERIMENTAL
Intervention: 75th percentile with incentives (n = 64)
Number of subjects: 286

Group type: EXPERIMENTAL
Intervention: 50th percentile without incentives (n = 80)
Number of subjects: 286

Group type: COMPARATOR
Intervention: 75th percentile without incentives (n = 44)
Number of subjects: 286
Study: 24196279

Group type: EXPERIMENTAL
Intervention: Intensity modulated radiotherapy (IMRT) with doses of 73.9 Gy (n = 41) and 76.2 Gy (n = 109) delivered in 32 and 33 fractions, respectively.
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: Intensity modulated radiotherapy (IMRT) with doses of 73.9 Gy and 76.2 Gy.
Number of subjects: 150
Study: 22108449

Group type: EXPERIMENTAL
Intervention: Stretta procedure
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: Sildenafil (esophageal smooth muscle relaxant)
Number of subjects: 22

Group type: COMPARATOR
Intervention: Sham treatment
Number of subjects: 22
Study: 19915736

Group type: EXPERIMENTAL
Intervention: Isoflavone (100 mg/day for 4 months)
Number of subjects: 38

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 38
Study: 17846017

Group type: COMPARATOR
Intervention: ABVD alone
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: Radiation therapy
Number of subjects: 33
Study: 14639137

Group type: EXPERIMENTAL
Intervention: Epsilon-aminocaproic acid (epsilon-ACA) prior to skin incision (bolus 150 mg/kg, followed by an infusion at 15 mg x kg(‐1) x hr(‐1))
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Epsilon-aminocaproic acid (epsilon-ACA) after heparin (same doses)
Number of subjects: 90

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 90
Study: 12666969

Group type: EXPERIMENTAL
Intervention: Sonicare toothbrush in active mode ('on')
Number of subjects: 20

Group type: COMPARATOR
Intervention: Sonicare toothbrush in manual mode ('off')
Number of subjects: 20
Study: 8865950

Group type: EXPERIMENTAL
Intervention: High school alcohol misuse prevention program
Number of subjects: 1041
Study: 1624202

Group type: EXPERIMENTAL
Intervention: Concept 45 degrees toothbrush
Number of subjects: 36

Group type: COMPARATOR
Intervention: Control toothbrush
Number of subjects: 36
Study: 6528617

Group type: EXPERIMENTAL
Intervention: Substitution of antithrombin III (AT III)
Number of subjects: 16

Group type: COMPARATOR
Intervention: No substitution of antithrombin III (Control group)
Number of subjects: 16
Study: 31377477

Group type: EXPERIMENTAL
Intervention: Lapatinib (1500 mg/day)
Number of subjects: 455

Group type: EXPERIMENTAL
Intervention: Trastuzumab (common dose)
Number of subjects: 455

Group type: EXPERIMENTAL
Intervention: Lapatinib (1000 mg/day) plus Trastuzumab
Number of subjects: 455

Group type: EXPERIMENTAL
Intervention: pCR (pathologic complete response)
Number of subjects: 455
Study: 28032343

Group type: EXPERIMENTAL
Intervention: High-density surface electromyography tracking method
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: Endurance training (cycling)
Number of subjects: 17
Study: 25581856

Group type: EXPERIMENTAL
Intervention: OND OSF 8 mg (ZUPLENZ)
Number of subjects: 114

Group type: COMPARATOR
Intervention: OND ODT 8 mg (ZOFRAN)
Number of subjects: 114
Study: 23511031

Group type: EXPERIMENTAL
Intervention: Ciprofloxacin (500 mg twice daily)
Number of subjects: 33

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: Ciprofloxacin
Number of subjects: 33
Study: 21874215

Group type: EXPERIMENTAL
Intervention: Combined aerobic endurance and resistance muscle training
Number of subjects: 60

Group type: COMPARATOR
Intervention: Aerobic endurance training
Number of subjects: 60
Study: 19833273

Group type: EXPERIMENTAL
Intervention: 0.5% bupivacaine (5 mg) with 2-minute sitting position after injection
Number of subjects: 180

Group type: EXPERIMENTAL
Intervention: 0.5% bupivacaine (5 mg) with 5-minute sitting position after injection
Number of subjects: 180

Group type: EXPERIMENTAL
Intervention: 0.5% bupivacaine (5 mg) with 10-minute sitting position after injection
Number of subjects: 180
Study: 16720940

Group type: EXPERIMENTAL
Intervention: Respiratory muscle strength training technique
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: Respiratory muscle strength training
Number of subjects: 28
Study: 16533192

Group type: EXPERIMENTAL
Intervention: Botulinum toxin B
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study: 10371004

Group type: EXPERIMENTAL
Intervention: Stabilisation appliance
Number of subjects: 60

Group type: COMPARATOR
Intervention: Control appliance
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Background variable - Male sex
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Background variable - Severe or very severe TMJ pain
Number of subjects: 60
Study: 8879466

Group type: EXPERIMENTAL
Intervention: 25‐mg CMI slow infusion
Number of subjects: 27

Group type: COMPARATOR
Intervention: 25‐mg CMI tablet
Number of subjects: 27
Study: 2000648

Group type: EXPERIMENTAL
Intervention: Compression antiembolism stocking (T.E.D.)
Number of subjects: 149

Group type: COMPARATOR
Intervention: Ace-bandage
Number of subjects: 149
Study: 6838322

Group type: EXPERIMENTAL
Intervention: Clonidine hydrochloride
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Imipramine hydrochloride
Number of subjects: 6

Group type: COMPARATOR
Intervention: Placebo treatment
Number of subjects: 6
Study: 31083777

Group type: EXPERIMENTAL
Intervention: Nasal high-flow (NHF) therapy at 45 L/min
Number of subjects: 24

Group type: COMPARATOR
Intervention: Non-invasive ventilation (NIV) at 15/4 cm H2O
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Nasal high-flow (NHF) therapy
Number of subjects: 24
Study: 29600719

Group type: EXPERIMENTAL
Intervention: Platelet-Rich Plasma (PRP) injection
Number of subjects: 80

Group type: COMPARATOR
Intervention: Corticosteroid injection
Number of subjects: 80
Study: 27551113

Group type: EXPERIMENTAL
Intervention: Elective neck dissection in conjunction with primary surgery
Number of subjects: 0

Group type: COMPARATOR
Intervention: Primary surgery alone
Number of subjects: 0
Study: 25349301

Group type: EXPERIMENTAL
Intervention: Gemcitabine 1,000 mg/m² and carboplatin AUC 2 plus iniparib 5.6 mg/kg (GCI)
Number of subjects: 519

Group type: COMPARATOR
Intervention: Gemcitabine 1,000 mg/m² and carboplatin AUC 2 (GC)
Number of subjects: 519

Group type: EXPERIMENTAL
Intervention: Gemcitabine 1,000 mg/m² and carboplatin AUC 2 plus iniparib 5.6 mg/kg (GCI) in second-/third-line treatment
Number of subjects: 519
Study: 22293533

Group type: EXPERIMENTAL
Intervention: PHX1766 800 mg twice daily
Number of subjects: 70

Group type: COMPARATOR
Intervention: PHX1766 (various doses: 50 mg once daily - 1000 mg once daily, 250 mg twice daily)
Number of subjects: 70

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 70
Study: 20415623

Group type: EXPERIMENTAL
Intervention: Cyclosporine 0.05%
Number of subjects: 58

Group type: COMPARATOR
Intervention: Artificial tears
Number of subjects: 58
Study: 18567089

Group type: EXPERIMENTAL
Intervention: Da Cheng Qi Decoction enema and external use of Glauber's salt, once a day for 7 days.
Number of subjects: 80

Group type: COMPARATOR
Intervention: Normal saline (NS) enema.
Number of subjects: 80
Study: 15929749

Group type: COMPARATOR
Intervention: Proton pump inhibitors (PPIs)
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: PPI test
Number of subjects: 8
Study: 12739240

Group type: EXPERIMENTAL
Intervention: Steroid treatment
Number of subjects: 36

Group type: COMPARATOR
Intervention: Nonsteroid treatment
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Steroid treatment in cases with persistent canal paresis
Number of subjects: 36

Group type: COMPARATOR
Intervention: Nonsteroid treatment in cases with persistent canal paresis
Number of subjects: 36
Study: 10595814

Group type: EXPERIMENTAL
Intervention: Intravenous immunoglobulin (IVIg) prophylaxis (500 mg/kg/d loading from day -6 to -1 and then 100 mg/kg every 3 days from day 3 to 90)
Number of subjects: 241

Group type: EXPERIMENTAL
Intervention: Intravenous immunoglobulin (IVIg) prophylaxis
Number of subjects: 241

Group type: COMPARATOR
Intervention: Control group (no IVIg)
Number of subjects: 241
Study: 9138980

Group type: EXPERIMENTAL
Intervention: N-acetyltransferase (NAT) and catalase activity in complicated pregnancies
Number of subjects: 141

Group type: COMPARATOR
Intervention: N-acetyltransferase (NAT) and catalase activity in physiological pregnancies (control group)
Number of subjects: 141
Study: 1924655

Group type: EXPERIMENTAL
Intervention: Finger temperature feedback
Number of subjects: 31

Group type: COMPARATOR
Intervention: Autogenic training
Number of subjects: 31
Study: 31432216

Group type: EXPERIMENTAL
Intervention: Extracorporeal CO2 removal (ECCO2R)
Number of subjects: 95
Study: 29094998

Group type: EXPERIMENTAL
Intervention: Nutritional oral formula (GS)
Number of subjects: 99

Group type: COMPARATOR
Intervention: Nutritional oral formula (GS) and Control (GC)
Number of subjects: 99
Study: 25946948

Group type: EXPERIMENTAL
Intervention: EMLA 5% cream applied to the cervix
Number of subjects: 92

Group type: COMPARATOR
Intervention: Placebo cream applied to the cervix
Number of subjects: 92
Study: 23627684

Group type: EXPERIMENTAL
Intervention: Tailored intervention (three participatory workshops and organization-wide educational activities)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Standard care (print resources)
Number of subjects: 16
Study: 21906521

Group type: EXPERIMENTAL
Intervention: Tian Gui Capsule
Number of subjects: 47

Group type: COMPARATOR
Intervention: metformin
Number of subjects: 47

Group type: COMPARATOR
Intervention: Diane‐35
Number of subjects: 47
Study: 18710712

Group type: EXPERIMENTAL
Intervention: Recombinant human leukemia inhibitory factor, 150 microg SC twice daily for 7 days
Number of subjects: 149

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 149
Study: 17584010

Group type: EXPERIMENTAL
Intervention: 50-mg sildenafil
Number of subjects: 16

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study: 15209835

Group type: EXPERIMENTAL
Intervention: Fluoxetine
Number of subjects: 330

Group type: EXPERIMENTAL
Intervention: Nortriptyline
Number of subjects: 330

Group type: EXPERIMENTAL
Intervention: Cognitive behaviour therapy
Number of subjects: 330
Study: 11275293

Group type: EXPERIMENTAL
Intervention: Melatonin administration at 0700 h
Number of subjects: 9

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Melatonin administration
Number of subjects: 9
Study: 9533119

Group type: EXPERIMENTAL
Intervention: Pulsatile flow during CPB
Number of subjects: 20

Group type: COMPARATOR
Intervention: Nonpulsatile flow during CPB
Number of subjects: 20
Study: 7915672

Group type: EXPERIMENTAL
Intervention: Intravenous saline and a breathing mixture of even parts of oxygen and nitrous oxide (Entonox)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Intravenous ketobemidone hydrochloride 2.5 mg, midazolam 2.5 mg, and breathing air from a face mask with a demand valve (KHM)
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Entonox
Number of subjects: 50
Study: 2610800

Group type: EXPERIMENTAL
Intervention: Cantharis
Number of subjects: 34

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 34
Study: 1103206

Group type: EXPERIMENTAL
Intervention: Haloperidol
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Chlorpromazine
Number of subjects: 20
Study: 31879235

Group type: EXPERIMENTAL
Intervention: Active treatment plus standard of care (SOC)
Number of subjects: 131

Group type: COMPARATOR
Intervention: Sham treatments plus SOC
Number of subjects: 131
Study: 31142310

Group type: EXPERIMENTAL
Intervention: Cage positioning (posteriorly located cages)
Number of subjects: 953

Group type: COMPARATOR
Intervention: Control group (100 patients without PCM)
Number of subjects: 953
Study: 29233087

Group type: EXPERIMENTAL
Intervention: Rehabilitation manual
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Manual plus pedometer
Number of subjects: 15

Group type: COMPARATOR
Intervention: Standard/usual care
Number of subjects: 15
Study: 26693193

Group type: EXPERIMENTAL
Intervention: Behavioural Graded Activity (BGA)
Number of subjects: 62

Group type: COMPARATOR
Intervention: Conventional Exercise Therapy (CET)
Number of subjects: 62
Study: 23311458

Group type: EXPERIMENTAL
Intervention: Employee wellness programme based on cognitive behaviour therapy (CBT) and weekly supervised exercise classes over six weeks.
Number of subjects: 80

Group type: COMPARATOR
Intervention: Once‐off health promotion talk and educational pamphlets (control group).
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Employee wellness programme (experimental group).
Number of subjects: 80

Group type: COMPARATOR
Intervention: Control group (once‐off health promotion talk).
Number of subjects: 80
Study: 21676046

Group type: EXPERIMENTAL
Intervention: Örebro prevention programme (ÖPP)
Number of subjects: 1752

Group type: COMPARATOR
Intervention: No intervention (control)
Number of subjects: 1752
Study: 18772058

Group type: EXPERIMENTAL
Intervention: Percutaneous coronary intervention (PCI)
Number of subjects: 7513

Group type: COMPARATOR
Intervention: Medical treatment
Number of subjects: 7513
Study: 16139813

Group type: EXPERIMENTAL
Intervention: Olanzapine (mean dose 8.7 +/- 7.1 mg/day)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study: 12975627

Group type: EXPERIMENTAL
Intervention: Dynamic treatment protocol consisting of 4 different subprotocols
Number of subjects: 0
Study: 11076409

Group type: EXPERIMENTAL
Intervention: Osmo-adalat 30 mg once daily for 3 weeks
Number of subjects: 60

Group type: COMPARATOR
Intervention: Cordipin 10 mg three times a day
Number of subjects: 60
Study: 8826515

Group type: EXPERIMENTAL
Intervention: Pressure applied to highly tender muscle
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Pressure applied to normal muscle
Number of subjects: 80

Group type: COMPARATOR
Intervention: Pericranial myofascial tenderness evaluation
Number of subjects: 80
Study: 1526880

Group type: EXPERIMENTAL
Intervention: Groin dissection
Number of subjects: 58

Group type: COMPARATOR
Intervention: Groin radiation
Number of subjects: 58
Study: 3890049

Group type: EXPERIMENTAL
Intervention: Prazosin
Number of subjects: 60

Group type: COMPARATOR
Intervention: Atenolol
Number of subjects: 60